ライフサイエンスコーパス: C-reactive protein

1 IL (interleukin)-6 and high-sensitivity CRP (C-reactive protein).

2 cose; systolic and diastolic blood pressure; C-reactive protein).

3 eam clinical biomarker high-sensitivity CRP (C-reactive protein).

4 l analog scale for general health) and DAS28-C-reactive protein.

5 ing, hormone therapy, physical activity, and C-reactive protein.

6 s on fasting plasma glucose, and 5 trials on C-reactive protein.

7 r lymphocyte count, but elevated D-dimer and C-reactive protein.

8 ffects on increased hematocrit and decreased C-reactive protein.

9 these sites correlated with plasma levels of C-reactive protein.

10 nforced by our finding of elevated levels of C-reactive protein.

11 biomarkers were HbA1c, total cholesterol and C-reactive protein.

12 yte sedimentation rate and 0.73 and 0.78 for C-reactive protein.

13 nfarction and elevations in high-sensitivity C-reactive protein.

14 ipoprotein cholesterol, and high-sensitivity C-reactive protein.

15 .65 (95% CI, 1.13-2.41) for high-sensitivity C-reactive protein.

16 he effects of parental Holocaust exposure on C-reactive protein.

17 f specific targets, demonstrated herein with C-reactive protein.

18 Median C-reactive protein [138 mg/L (IQR: 83-179) vs 73 mg/L (I

19 ients with persistent symptoms and/or raised C-reactive protein 14 days after a COPD exacerbation, an

20 ll living (7.5 versus 5.7x10(3)/mul), as was C-reactive protein (163 versus 80 mg/L).

21 ll counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-di

22 .3 (3.4-13.0) ng/L, hs-CRP (high sensitivity C-reactive protein) 2.8 (1.3-6.1) mg/L, uric acid 7.2 (5

23 stent with marked inflammation, for example, C-reactive protein (229 mg/L [IQR, 156-338], assessed in

24 9 to 861.42 +/- 724.82 ng/mL; P < 0.001) and C-reactive protein (6.05 +/- 8.99 to 2.49 +/- 2.89 mg/L;

25 with type-2 diabetes and elevated levels of C-reactive protein, a marker of chronic inflammation.

26 neutrophil, lymphocyte, and platelet counts, C-reactive protein, albumin, bilirubin, and CA19-9 level

27 tomatic adverse events, faecal calprotectin, C-reactive protein, albumin, platelet count, 25(OH) vita

28 ment of candidate DNA methylation related to C-reactive protein and body mass index (aircraft, road t

29 vels of interleukin-1beta, interleukin-6, or C-reactive protein and did not result in fewer cardiovas

30 ntly used biomarkers such as HLA-B27 status, C-reactive protein and erythrocyte sedimentation rate ha

31 res (based on clinical factors and levels of C-reactive protein and fecal calprotectin), at pediatric

32 ons in inflammation (based on serum level of C-reactive protein and fecal level of calprotectin) and

33 We analyzed maternal plasma high-sensitivity C-reactive protein and glycoprotein acetyls at 3 consecu

34 Higher levels of maternal high-sensitivity C-reactive protein and glycoprotein acetyls at and acros

35 C-reactive protein and IL-6 were assessed at each wave,

36 increased markers of inflammation, including C-reactive protein and IL-6.

37 ionally, mediation effects of high-sensitive C-reactive protein and interleukin-6 (IL6) measured in b

38 ocytes, and increased inflammatory proteins (C-reactive protein and interleukin-6).

39 te, CD4(+), and neutrophil counts; increased C-reactive protein and interleukin-6; and more severe de

40 two immunoassays to determine the biomarkers C-reactive protein and lactate dehydrogenase (detection

41 rs, and cardiac troponin in addition to high C-reactive protein and procalcitonin levels.

42 association between inflammation measured as C-reactive protein and SEP across four countries (Britai

43 kines (tumor necrosis factor, high sensitive C-reactive protein) and adipokines (adiponectin, leptin)

44 d but rapidly normalized in parallel to CRP (C-reactive protein) and cytokine level reduction.

45 ted inflammatory markers (ferritin, D-dimer, C-reactive protein) and elevated neutrophil:lymphocyte r

46 CRP (C-reactive protein) and IL (interleukin)-6 plasma concen

47 esults suggest that it is unlikely that CRP (C-reactive protein) and vitamin D play causal roles of a

48 and inflammatory markers such as leptin and C-reactive protein), and 24 were higher in men (includin

49 objective signs of inflammation (via MRI or C-reactive protein), and an inadequate response or intol

50 o-B-type natriuretic peptide), hs-cTnT, CRP (C-reactive protein), and circulating oxidative stress bi

51 ating Scale and hemoglobin, plasma ferritin, C-reactive protein, and alpha1-acid glycoprotein were as

52 se, tissue inhibitor of metalloproteinase 1, C-reactive protein, and bile acids than nonresponders.

53 We investigated IL6, C-reactive protein, and circulating cell-free mtDNA in s

54 igand 2, lipopolysaccharide-binding protein, C-reactive protein, and interleukin 6 were differentiall

55 no overall differences in serum IL-6, IL-10, C-reactive protein, and length of stay.

56 obin, N-terminal B-type natriuretic peptide, C-reactive protein, and leukocyte count.

57 Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the r

58 al laboratories (alanine aminotransferase 1, C-reactive protein, and myoglobin).

59 ower PaO2/FIO2 ratio, higher D-dimer, higher C-reactive protein, and receipt of mechanical ventilatio

60 6, -8, and -10, tumor necrosis factor-alpha, C-reactive protein, and S-100beta levels in quartile 4 w

61 6, -8, and -10, tumor necrosis factor-alpha, C-reactive protein, and S-100beta levels in quartile 4 w

62 association but tumor necrosis factor-alpha, C-reactive protein, and S-100beta lost their association

63 mean arterial pressure, blood urea nitrogen, C-Reactive protein, and the international normalized rat

64 blood glucose, LDL-to-HDL cholesterol ratio, C-reactive protein, angiotensin II, and albuminuria redu

65 rsity score (aOR: 0.75; 95% CI: 0.56, 0.99), C-reactive protein (aOR: 0.82; 95% CI: 0.73, 0.92), Heli

66 d levels of serum Krebs von den Lungen-6 and C-reactive protein are both associated with SSc-ILD seve

67 t metastasis or high pre-operative levels of C-reactive protein, as Piwi-like 1 positivity was associ

68 n, parathyroid hormone, and high-sensitivity C-reactive protein at 1 year; fewer headaches, dizziness

69 C-reactive protein at baseline had an AUC of 0.73 (0.6-0

70 aseline, body-mass index at baseline, cause, C-reactive protein at baseline, baseline FEV(1) percenta

71 judged by significant decrease of fever and C-reactive protein at day 3.

72 ely observed in the absence of inflammatory (C-reactive protein) changes and were associated with bot

73 In some persons C-reactive protein clearly dropped only after the second

74 High-sensitivity C-reactive protein concentration also increased less aft

75 atus, International Staging System, age, and C-reactive protein concentration as prognostic variables

76 sed a linear model to assess log-transformed C-reactive protein concentration following radiotherapy

77 disease-modifying antirheumatic drug use and C-reactive protein concentration) to subcutaneous inject

78 tance, total cholesterol, triglycerides, and C-reactive protein concentrations (P values < 0.05).

79 crease in interleukin-6 and high-sensitivity C-reactive protein concentrations after PCI when compare

80 significant difference between all diets for C-reactive protein concentrations and markers of glucose

81 d melatonin positively associated with serum C-reactive protein concentrations.

82 pressure, and insulin, glucose, lipids, and C-reactive protein concentrations.

83 orting the recent observations that IL-6 and C-reactive protein could be used as markers for COVID-19

84 atal sepsis including Serum Amyloid A (SAA), C - reactive protein (CRP), Procalcitonin (PCT) and Lipo

85 tal status, oral inflammatory load and serum C- reactive protein (CRP) level, and infant birth weight

86 9/L (adjusted OR, 3.56 [95% CI, 1.27-9.97]), C-reactive protein (CRP) >100 mg/L (adjusted OR, 2.71 [9

87 moglobin <8.5 g/dL as predictive of IRIS and C-reactive protein (CRP) >106 mug/mL and BMI <15.6 kg/m2

88 sponsive to the clinically required range of C-reactive protein (CRP) (0.005 - 500 mg L(-1); r(2) = 0

89 aimed to model the inflammatory response of C-reactive protein (CRP) and alpha-1-acid glycoprotein (

90 oncentrations of the inflammation biomarkers C-reactive protein (CRP) and alpha1-acid glycoprotein (A

91 o enhance the sensing performance on antigen C-reactive protein (CRP) and anti-CRP antibody binding e

92 A decrease in serum C-reactive protein (CRP) and bacterial colony forming un

93 s compared with that of measurement of serum C-reactive protein (CRP) and fecal calprotectin.

94 lected by increased plasma concentrations of C-reactive protein (CRP) and fibrinogen, is associated w

95 inequalities in inflammation -assessed using C-reactive protein (CRP) and fibrinogen- varied across t

96 changes in serum-levels of markers including C-reactive protein (CRP) and Interleukin 6 (IL-6) measur

97 only measured systemic inflammatory markers, C-reactive protein (CRP) and interleukin-6 (IL-6).

98 Additionally, the impact of C-reactive protein (CRP) and platelet count was also ana

99 study was to assess the sensitivity of blood C-reactive protein (CRP) and procalcitonin (PCT) measure

100 bling femtomolar levels of quantification of C-reactive protein (CRP) and recovery in spiked serum sa

101 entrations of inflammation biomarkers, e.g., C-reactive protein (CRP) and/or alpha1-acid-glycoprotein

102 hat triglycerides, interleukin-6 (IL-6), and C-reactive protein (CRP) are likely causal risk factors

103 to determine diagnostic performance of serum C-reactive protein (CRP) as a triage test for tuberculos

104 ide clinics-where symptoms worsen and plasma C-reactive protein (CRP) becomes elevated.

105 e primary endpoint was the rate of change in C-reactive protein (CRP) degraded by matrix metalloprote

106 unoassay (MIm) has smartly been designed for C-reactive protein (CRP) determination in plasma of pret

107 detection was explored as a new approach for C-reactive protein (CRP) determination in serum and pret

108 Inflammatory markers like C-reactive protein (CRP) have been associated with post-

109 f 3 nM and capable of the detection of human C-reactive protein (CRP) in clinically relevant fluids.

110 w-density lipoprotein cholesterol (LDLc) and C-reactive protein (CRP) in patients with chronic kidney

111 ar increase in LOY was associated with lower C-reactive protein (CRP) in premenopausal (-11.5%; 95% C

112 er solution, and the successful detection of c-reactive protein (CRP) in serum compatible with 3-tier

113 mance were verified through the detection of C-reactive protein (CRP) in serum.

114 ate, reproducible and immediate detection of C-reactive protein (CRP) in the wide concentration range

115 Peripheral blood C-reactive protein (CRP) is a biomarker used clinically

116 C-reactive protein (CRP) is an acute-phase protein produ

117 e pain on postoperative day (POD)1; decrease C-Reactive protein (CRP) level on POD3; improve range of

118 (BNP) levels (HR 1.45; 95% CI 1.15-1.81) and C-reactive protein (CRP) levels (HR 1.02; 95% CI 1.00-1.

119 The assay also measures C-reactive protein (CRP) levels as an indicator of infla

120 ar increase in LOY was associated with lower C-reactive protein (CRP) levels in both premenopausal (d

121 pressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizuma

122 Point-of-care testing of C-reactive protein (CRP) may be a way to reduce unnecess

123 sistent negative association between PZC and C-reactive protein (CRP) or alpha-1-acid glycoprotein (A

124 ceptor agonist (IL-1RA) and high-sensitivity C-reactive protein (CRP) paired with xenobiotic-induced

125 jective of this trial was to explore whether C-reactive protein (CRP) testing at point of care could

126 unts, lower lymphocyte counts, and increased C-reactive protein (CRP) than patients with nonsevere in

127 The safety and efficacy of using C-reactive protein (CRP) to decide on antibiotic prescri

128 lesterol, HDL cholesterol, apoA-I, apoB, and C-reactive protein (CRP) were analyzed and non-HDL chole

129 Levels of ADMA and C-reactive protein (CRP) were assessed with a commercial

130 nd 23, brain derived neurotrophic factor and C-reactive protein (CRP) were further validated using im

131 Leptin, insulin, and C-reactive protein (CRP) were measured using electrochem

132 the associations of hair cortisol and plasma C-reactive protein (CRP) with the longitudinal persisten

133 mmation (alpha-1-acid glycoprotein (AGP) and C-reactive protein (CRP)) were measured at 6 and 18 mo.

134 The genetic determinants of C-reactive protein (CRP), a biomarker of chronic inflamm

135 e examined the association of AMH with serum c-reactive protein (CRP), a biomarker of inflammation, i

136 We measured C-reactive protein (CRP), a marker of systemic inflammat

137 Elevated levels of C-reactive protein (CRP), a sensitive marker of inflamma

138 c), insulin resistance (HOMA-IR), uric acid, C-reactive protein (CRP), alanine transaminase (ALT), as

139 Weight loss, performance status (PS), C-reactive protein (CRP), albumin, the nutritional risk

140 Concentrations of C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP

141 and certain micronutrient biomarkers such as C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP

142 d anthropometric and periodontal parameters, C-reactive protein (CRP), and fibrinogen as markers of i

143 s disease activity index (CDAI), fCal, serum C-reactive protein (CRP), and haemogram.

144 Chitinase-3-like protein 1 (CHI3L1), C-reactive protein (CRP), and interleukin-6 (IL-6) were

145 etween a circulating marker of inflammation, C-reactive protein (CRP), and ovarian cancer risk has be

146 ovulatory cycle years (LOY) and circulating C-reactive protein (CRP), counter to their hypothesis.

147 latory years (LOY) and circulating levels of C-reactive protein (CRP), counter to their hypothesis.

148 robable association with older age; elevated C-reactive protein (CRP), D-dimer, and fibrinogen levels

149 ry biomarker analysis, circulating levels of C-reactive protein (CRP), IL6, IL18, IL1 receptor antago

150 ), lipopolysaccharide binding protein (LBP), C-reactive protein (CRP), ILT-4, C-C motif ligand 18 (PA

151 of inflammation, including high-sensitivity C-reactive protein (CRP), interleukin (IL)-6, interferon

152 ell activation, and the inflammatory markers C-reactive protein (CRP), interleukin 6 (IL-6), and tumo

153 Genetically elevated circulating levels of C-reactive protein (CRP), interleukin-1 receptor antagon

154 Herein four such CVDs biomarkers- C-reactive protein (CRP), N-terminal pro b-type natriure

155 olic and diastolic blood pressure, increased C-reactive protein (CRP), reduced HDL, insulin resistanc

156 The tertiary outcome was the serum level of C-reactive protein (CRP), serum amyloid P (SAP), and alp

157 Secondary outcomes were changes in plasma C-reactive protein (CRP), the diversity of the faecal mi

158 ine responsiveness was associated with serum C-reactive protein (CRP), tumor necrosis factor, interle

159 ipopolysaccharide binding protein (LBP), and C-reactive protein (CRP), were elevated in sera, and cor

160 hormone (AMH) and miR-93-3p correlated with C-reactive protein (CRP).

161 els of triglycerides, total cholesterol, and C-reactive protein (CRP).

162 assay is validated for the determination of C-reactive Protein (CRP).

163 provided blood samples for the assessment of C-reactive protein (CRP).

164 Tumor Necrosis Factor-Alpha (TNF-alpha), and C-reactive protein (CRP)] in community samples, both una

165 VD biomarkers such as S100 beta proteins and C-reactive proteins (CRP).

166 (BMI), admission biomarkers of inflammation (C-reactive protein [CRP] level and erythrocyte sedimenta

167 stemic inflammation (as shown by an elevated C-reactive protein [CRP] level).

168 osis factor receptor-1, procalcitonin [PCT], C-reactive protein [CRP]) activation pathways were deter

169 -individual changes in acute phase proteins (C-reactive protein [CRP], alpha-1-acid glycoprotein [AGP

170 iated with altered kinetics of inflammatory (C-Reactive Protein [CRP], Chitinase 3-like protein-1 [CH

171 ammatory hypercoagulable state with elevated C-reactive protein, D-dimer, and ferritin.

172 Elevated levels of C-reactive protein, d-dimer, and troponin were found in

173 ned as 28-joint Disease Activity Score using C-reactive protein (DAS28[CRP]) of 3.2 or lower, both wi

174 mission (disease activity score in 28 joints-C-reactive protein [DAS28-CRP] <3.2 and no swollen joint

175 owing tests: erythrocyte sedimentation rate, C-reactive protein, fecal lactoferrin, fecal calprotecti

176 omes, and its addition to a 3-BRS comprising C-reactive protein, fibrin degradation product, and heat

177 lammation (IL-6, TNF-alpha, high-sensitivity C-reactive protein, fibrinogen, and albumin), and bone m

178 erinflammation (ferritin >=1000 ng/mL and/or C-reactive protein >10 mg/dL) and respiratory failure (o

179 residual inflammatory risk (high-sensitivity C-reactive protein >= 2 mg/l).

180 t three swollen and three tender joints; and C-reactive protein >=0.3 mg/dL) despite standard therapi

181 len joints, at least five tender joints, and C-reactive protein >=0.6 mg/dL) despite standard therapi

182 r myocardial infarction and high-sensitivity C-reactive protein >=2 mg/L to canakinumab 50, 150, or 3

183 ipheral white blood cell count >=20 000/mm3, C-reactive protein >=70.0 mg/L, and serum sodium <135 mE

184 IV COPD and persistent symptoms and/or serum C-reactive protein >=8 mg/L initiated 14 (+/-3) days aft

185 nflammatory signals, including cytokines and C-reactive protein, have been described in posttraumatic

186 reased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleuk

187 High-sensitivity C-reactive protein (hs-CRP) is independently associated

188 esion molecule 1 (sICAM-1), high sensitivity C-reactive protein (hs-CRP), and alpha1-acid glycoprotei

189 nomic status, serum lipids, high-sensitivity C-reactive protein (hs-CRP), and for plasma and salivary

190 ine metabolites, neopterin, high-sensitivity C-reactive protein (hs-CRP), and lipids.

191 abolic biomarkers including high-sensitivity C-reactive protein (hs-CRP), estimated glomerular filtra

192 nfarction (MI) and elevated high-sensitivity C-reactive protein (hs-CRP).

193 ic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hs-CRP).

194 ine the association between high-sensitivity C-reactive protein (hsCRP) and both periodontitis and pe

195 lammatory markers including high-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated ph

196 lasma ANGPTL5, and obesity, high sensitivity C-reactive protein (HsCRP) and oxidized low-density lipo

197 LDL-C <=70 mg/dl and serial high-sensitivity C-reactive protein (hsCRP) assessments (at least 2 measu

198 ctor alpha (TNF-alpha), and high-sensitivity C-reactive protein (hsCRP) concentrations.

199 sis for inflammatory markers complemented by C-reactive protein (hsCRP) measurement, and proteomic ma

200 s for changes in lipids and high-sensitivity C-reactive protein (hsCRP) serum concentration were expr

201 h rising baseline levels of high-sensitivity C-reactive protein (hsCRP), and both hsCRP and IL-6 decr

202 cal mortality risk factors: high-sensitivity C-reactive protein (hsCRP), homeostatic model assessment

203 , following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardiovascular r

204 hat serum concentrations of high-sensitivity C-reactive protein (hsCRP), z-inflammation composite sco

205 ipids, fasting glucose, and high-sensitivity C-reactive protein (hsCRP).

206 mic inflammation, including high-sensitivity C-reactive protein, IL6, d-dimer, and systemic tumor nec

207 4A together with their binding partners, and C-reactive protein in a complex with its antibody.

208 me ovulatory years was associated with lower C-reactive protein in both premenopausal and postmenopau

209 support enabling the reagentless assaying of C-reactive protein in serum with good sensitivity.

210 iple biomarkers (troponin, procalcitonin and C-Reactive Protein) in parallel in undiluted urine sampl

211 pe natriuretic peptide), or high-sensitivity C-reactive protein individually or in combination could

212 easured circulating inflammatory biomarkers (C-reactive protein, interleukin 6, interleukin 10, tumor

213 adhesion molecule, thrombomodulin, endocan, C-reactive protein, interleukin-6, and interleukin-8 wer

214 thrombomodulin) and inflammatory biomarkers (C-reactive protein, interleukin-6, and interleukin-8) we

215 Higher levels of C-reactive protein, interleukin-6, intercellular adhesio

216 osely associated with this infection such as C-reactive proteins, interleukin-6, procalcitonin and fe

217 C-reactive protein is involved in ovarian carcinogenesis

218 riodontal parameters were recorded and serum C-reactive protein level (CRP) was assessed.

219 se Activity Score for 28 joints based on the C-reactive protein level (DAS28-CRP; range, 0 to 9.4, wi

220 lactate dehydrogenase level (P < .001), and C-reactive protein level (P = .042).

221 count, hypoalbuminemia, troponin level, and C-reactive protein level and the interactions among thes

222 Laboratory tests revealed an increased C-reactive protein level of 133 mg/L (normal range, 0.2-

223 ) (normal range, 0-60 U/L [0-1.0 ukat/L]), a C-reactive protein level of 159 mg/L (1514 nmol/L) (norm

224 hour (normal range, 0-30 mm per hour), and a C-reactive protein level of 203.8 mg/L (1940.9 nmol/L) (

225 hour (normal range, 0-30 mm per hour), and a C-reactive protein level of 203.8 mg/L (1940.9 nmol/L) (

226 elevant blood tests at this stage revealed a C-reactive protein level of 206 mg/L (normal range, 0-10

227 ytopenia was observed in 95 (60%), increased C-reactive protein level was observed in 139 (88%), and

228 White blood cell count and C-reactive protein level were elevated, and hepatic enzy

229 level, 36 mg/dL; and median high-sensitivity C-reactive protein level, 2.1 mg/L), 12 633 (96.6%) comp

230 obesity, an elevated d-dimer value, elevated C-reactive protein level, and a rising d-dimer value ove

231 High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) le

232 disease, symptom duration, neutrophil count, C-reactive protein level, lactate dehydrogenase level, d

233 Complete blood count, C-reactive protein level, sedimentation rate, and creati

234 -0.10; 95% CI, -1.23 to 1.03; P = .86) or in C-reactive protein levels (54.1 vs 46.1 mug/mL; differen

235 uently also showed elevated high-sensitivity C-reactive protein levels (6.0 mg/L versus 1.4 mg/L in p

236 body mass index (BMI) (P = 0.003), elevated C-reactive protein levels (P = 0.003), and decreased HDL

237 blood pressure, and serum lipid, leptin, and C-reactive protein levels at age 4 years.

238 ts had significantly higher highly sensitive-C-reactive protein levels compared to Controls (2.1 +/-

239 me ovulatory years was associated with lower C-reactive protein levels in both premenopausal and post

240 n lower interleukin-1beta, interleukin-6, or C-reactive protein levels than placebo.

241 ocedure revealed that most cases with normal C-reactive protein levels that were classified as C. acn

242 Higher C-reactive protein levels were also associated with lowe

243 ours, and plasma biomarkers of inflammation (C-reactive protein levels) and vascular injury (thrombom

244 ose response, hepcidin, and high sensitivity C-reactive protein levels.

245 -B-type natriuretic peptide, troponin I, and C-reactive protein levels.

246 ic symptoms and higher lymphocyte counts and C-reactive protein levels.

247 olipoprotein B, galectin-3, high-sensitivity C-reactive protein, lipoprotein(a), N-terminal pro-B-typ

248 le (higher HDL cholesterol, lower BMI, lower C-reactive protein, lower waist circumference, and lower

249 e of absence of fever in the preceding week, C-reactive protein <20 mg/L, and reduction in abscess si

250 of sustained corticosteroid-free remission, C-reactive protein <=0.5 mg/dL, and level of fecal calpr

251 erence), and immune (white blood cell count, C-reactive protein) markers.

252 ions] observational study), high-sensitivity C-reactive protein (measured during EDIC years 4-6), and

253 % to -9.9%]; P < .001), and high-sensitivity C-reactive protein (median, -18.7% vs -9.4%; difference,

254 er elevation of inflammatory markers such as C-reactive protein (median, 229 mg/L [IQR 156-338] vs 67

255 od pressure; plasma lipids; high-sensitivity C-reactive protein; metabolic syndrome score; and glucos

256 osis, and proinflammatory markers, including C-reactive protein, MX1, IL-6, IL-1, IL-8, TNFalpha, and

257 was correlated with inflammatory biomarkers C-reactive protein, myeloperoxidase, and adiponectin red

258 stemic inflammatory responses as measured by C-reactive protein (n = 2), albumin (n = 2), white cell

259 atory (n=83; 55% obese), and obese high CRP (C-reactive protein; n=89; 98% obese).

260 Significant reductions in CRP (C-reactive protein), NT-proBNP (N-terminal pro-B-type na

261 harlson score, altered mental status, higher C-reactive protein on admission, need for mechanical ven

262 Ulcerative Colitis Activity Index score and C-reactive protein on days 3 and 5 of hospital admission

263 diseases (OR, 4.54; 95% CI, 1.36-15.10), and C-reactive protein (OR, 1.01; 95% CI, 1.01-1.02) increas

264 predictors of deterioration or death; as was C-reactive protein (OR, 2.1; 95% CI: 1.3, 3.4 per doubli

265 resulted in lower levels of calprotectin and C-reactive protein (P < 0.0001), coinciding with recover

266 d in a significant improvement at 2 years in C-reactive protein (p=0.012), insulin sensitivity index

267 is, body mass index, hyperferritinemia, high C-reactive protein, Pediatric Index of Mortality 3 score

268 diposity, more favorable biomarker profiles (C-reactive protein, plasma fibrinogen, white blood cell

269 s superior and incremental to interleukin-6, C-reactive protein, procalcitonin, ferritin, D-dimer, ca

270 e thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin myelofibrosis, renal dysfu

271 C-reactive protein, rheumatoid factor, antinuclear antib

272 Last, we showed that IL-6 and C-reactive protein serum concentrations were higher in p

273 antly greater reductions of high-sensitivity C-reactive protein, serum amyloid A, and fibrinogen from

274 ised in most patients on admission: elevated C-reactive protein, serum ferritin, procalcitonin, N-ter

275 CXCL10), lipopolysaccharide-binding protein, C-reactive protein, soluble CD163, and soluble scavenger

276 re obtained: interleukin 6, high-sensitivity C-reactive protein, soluble receptors for tumor necrosis

277 activator inhibitor-1, D-dimer, fibrinogen, C-reactive protein, sST2, galectin-3, cystatin-C, and ur

278 ment for any inflammation marker (IL-6, CRP [C-reactive protein], TNF-alpha R1, D-dimer, and fibrinog

279 awn to quantify five inflammatory biomarkers-C-reactive protein, tumor necrosis factor-alpha, and int

280 complexes streptavidin, concanavalin A, and C-reactive protein under charge reducing conditions.

281 Neonatal C-reactive protein was consistently associated with odds

282 High-sensitivity C-reactive protein was elevated beyond the clinical cuto

283 ferentiation factor-15, and high-sensitivity C-reactive protein was measured in 7,195 patients stabil

284 In contrast, C-reactive protein was not associated with current depre

285 was significantly increased by 24 h, whereas C-reactive protein was unchanged.

286 baseline concentrations of high-sensitivity C-reactive protein were higher among those who had HHF d

287 rylated neurofilament heavy chain (pNFH) and C-reactive protein were measured by ELISA in a longitudi

288 in 6, interleukin 1 receptor antagonist, and c-reactive protein were measured in serum.

289 n measures of body fat, glucose, insulin, or C-reactive protein were observed.

290 moking status, alcohol, and high-sensitivity C-reactive protein were performed to determine possible

291 Age, body mass index, and C-reactive protein were significantly associated with ar

292 s except glial fibrillary acidic protein and c-reactive protein were significantly elevated at the ea

293 Erythrocyte sedimentation rate and C-reactive protein were similar at discriminating organi

294 Serum lipids and markers of inflammation (C-reactive protein) were assessed for both oil types at

295 vated concentrations of IL-6, TNF-alpha, and C-reactive protein, which has been termed inflammaging.

296 Lower levels of C-reactive protein, white blood cell count, absolute neu

297 Lower levels of C-reactive protein, white blood cell count, absolute neu

298 nflammatory markers interleukin-6 (IL-6) and C-reactive protein with major depressive disorder are we

299 t (p = 0.059) increasing trend with dose for C-reactive protein with numbers of prior radiotherapy tr

300 ipoprotein cholesterol, and high sensitivity C-reactive protein, with potentially different potency a